Introduction
Artificial intelligence (AI)—defined as machine-based systems that generate predictions, recommendations, or decisions to address human-defined objectives—has become an integral component of clinical trial design by 2026. From electronic health record (EHR)-based patient identification to generative protocol drafting and real-time safety monitoring, AI is reshaping how trials are conceived, staffed, and executed. The Tufts Center for the Study of Drug Development documented 18% time savings in trial operations attributable to AI in January 2025, and AI-assisted patient screening tools have demonstrated up to a 95% reduction in per-file screening time relative to manual review 137. Yet these gains arrive alongside substantial governance obligations, persistent implementation barriers, and evolving—and sometimes divergent—regulatory expectations across the United States, European Union, and China. This narrative review synthesizes current evidence and regulatory guidance to help medical professionals understand the realistic state of AI in trial design as of mid-2026, distinguishing established applications from emerging or experimental ones.
Patient Recruitment and Enrollment
Failure to meet enrollment targets remains the most significant operational bottleneck in clinical development: approximately 80–85% of trials fail to achieve initial projections, and nearly 30% of sites enroll zero participants 23. AI-enabled recruitment tools address this by integrating EHR data, insurance claims, patient registries, and natural language processing (NLP) to identify eligible candidates, assess eligibility in near real time, and optimize site selection.
Performance evidence is encouraging. A prospective pilot at a large academic cancer center applied neural networks to radiology reports to identify patients likely to initiate new systemic therapy, linking output to a genomic matching platform (MatchMiner). The system reduced oncology nurse navigator review burden by 95%—from 60,199 matches to 3,168—while enabling identification of patients for early-phase precision oncology trials 8. Separately, a French single-center study of 9,876 patients using the SAS Viya platform demonstrated 96% precision and 94% recall in breast cancer trial prescreening, with screening time reduced from approximately five minutes to 20 seconds per file 7. A 2024 scoping review of AI recruitment tools across 51 studies reported 24–50% increases in accurate patient identification and reductions in screening timelines from a median of 19 days to minutes using commercially available platforms 4.
Site selection is a complementary application. DocTr, a cross-modal AI framework published in Nature Health in March 2026, integrated trial semantics (via ClinicalBERT embeddings), clinician patient-population vectors (ICD-10 encounter distributions), and historical trial engagement graphs (OpenPayments data) to match clinicians and sites to trials. Evaluated on 24,984 clinicians and 5,210 trials, DocTr achieved approximately 58% higher match similarity than leading baselines and improved race and ethnicity fairness entropy by 7% and 17%, respectively 26.
Limitations are substantial. Algorithmic bias was identified as a concern in 11 of the studies reviewed in 2024, with models trained on predominantly White or specialized-center cohorts performing poorly across broader populations 4. Privacy concerns regarding EHR data use without robust governance were cited in 15 studies. Alarm fatigue from false positives, data interoperability gaps across sites, and dependence on regularly updated trial databases were identified as additional operational barriers in qualitative interviews with oncology trial professionals 4. Fewer than 100 AI-related randomized controlled trials had been completed globally by 2024, underscoring a persistent "implementation gap" between technical capability and routine clinical practice 4.
Protocol Optimization
AI is increasingly used to accelerate and refine protocol development through feasibility assessment, endpoint selection, inclusion/exclusion criteria refinement, adaptive trial design, and simulation-based optimization. In March 2026, PhaseV launched AI Conductor, a platform that automates end-to-end trial workflows: generative AI drafts study components, statistical analysis plans aligned with ICH E9 standards are generated automatically, CDASH-aligned case report forms are produced from visit schedules, and submission-ready tables, listings, and figures (TLFs) are generated for FDA submission with a full audit trail 25. Platforms of this type represent a significant shift from isolated AI tools to orchestrated, integrated workflows.
Adaptive trial design and response-adaptive randomization (RAR) represent a more established domain. A systematic review of 65 RAR trials found a mean 22% reduction in sample size with none over-allocating patients to ineffective arms, and 85% of trials used Bayesian methods 10. However, 71% of all trials lacked clear statistical implementation details, and over 50% of those with results inadequately reported allocation changes—reflecting persistent reporting quality challenges 10. Similarly, a systematic review of 127 randomized platform trials found that nearly half did not report use of adaptive design features, and multiplicity adjustment for arms was unreported in 77.2% 9.
AI-assisted protocol optimization also encompasses synthetic and external control arms, endpoint refinement using real-world data, and simulation-based feasibility. The FDA's Framework for Digital Health Technologies (DHTs), finalized in 2025, provides stepwise guidance for validating DHT-derived endpoints, emphasizing early definition of the concept of interest, context of use (COU—defined as the specific role and scope of an AI model), and fit-for-purpose validation 2. Importantly, a 2024 scoping review of NLP and machine learning models for eligibility criteria parsing identified insufficient use of state-of-the-art AI models in clinical protocol analysis, suggesting that the promise of AI-assisted criteria refinement outpaces current deployment 6.
Critical limitations include the "black box" problem: complex deep learning models cannot readily explain recommendations to clinicians or regulators. Generative AI outputs remain prone to hallucination—plausible but erroneous content—requiring rigorous human review at every stage. Validation costs, dependence on historical trial data quality, and variable regulatory acceptance of synthetic control approaches represent additional barriers.
Regulatory Impact
By January 2026, the FDA and EMA jointly published ten Guiding Principles of Good AI Practice in Drug Development—the first major convergence of regulatory thinking on AI governance across the US–EU axis 115. These principles span human-centric design, risk-based oversight, adherence to technical and GxP standards, clear COU definition, multidisciplinary expertise, data governance, transparent model development practices, risk-based performance assessment, life cycle management, and plain-language communication 1. The FDA's January 2025 draft guidance on "Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products" provides a seven-step credibility assessment framework—from defining the question of interest through determining model adequacy—with emphasis on fit-for-use data that is both relevant and reliable 214.
The FDA's May 2026 launch of HALO (Harmonized AI and Lifecycle Operations for Data), which consolidates more than 40 application and submission data sources, and Elsa 4.0—its FedRAMP High-secured AI system—signals a fundamental shift from document-centric to data-centric regulatory review 28. The FDA also announced its real-time clinical trial (RTCT) program in April 2026, with proof-of-concept studies in mantle cell lymphoma and small cell lung carcinoma, enabling regulators to view safety signals as trials progress 29. This architecture raises new data quality and confidentiality risks: compressed quality control timelines may surface unverified signals, and HALO's cross-center data access creates potential confidential commercial information exposure 28.
In China, the NMPA has taken several steps aligning with FDA/EMA principles: a 30-day expedited clinical trial review pathway for eligible Class I innovative drugs was announced in September 2025 17; measures to support AI-powered medical devices—including simplified change registration where the core algorithm is unchanged—were issued in June 2025 1830; and information-sharing procedures for multinational trials have been established. Table 1: AI Applications in Clinical Trial Design—Benefits, Limitations, and Regulatory Status (2026)
| Application Domain | Key Technologies | Reported Benefits | Key Limitations and Risks | Regulatory Status (2026) |
|---|---|---|---|---|
| Patient Recruitment and EHR Matching | NLP, ML-based eligibility matching, EHR integration | Up to 95% reduction in screening time; 96% precision; 24–50% increase in patient identification | Algorithmic bias; privacy concerns; alarm fatigue; data interoperability gaps | No specific FDA/EMA approval pathway; prespecification encouraged; human oversight required |
| Trial Site Selection and Diversity | Cross-modal AI, graph embeddings, fairness optimization (DocTr) | 58% higher match accuracy; 7–17% improvement in race/ethnicity fairness entropy | US-centric; payment-data biases; enrollment prediction less robust (CCC 0.57) | Fairness metrics required; training data representativeness emphasized by FDA/EMA |
| Protocol Drafting | Generative AI (LLMs), version control, regulatory logic integration | Automated SDTM/ADaM generation; submission-ready outputs; reduced manual iteration | Hallucination risk; requires rigorous human review; audit trail complexity | Permitted with human oversight; outputs must pass quality control; prespecified in SAP |
| Adaptive Trial Design and RAR | Bayesian RAR, ML-assisted covariate adjustment, simulation | Mean 22% sample size reduction; improved ethical allocation | Reporting gaps (71% lack statistical detail); implementation complexity | FDA Adaptive Design guidance (2019) applicable; AI-specific expectations emerging |
| Endpoint Optimization and DHTs | Digital health technologies, wearables, AI-derived biomarkers | Continuous data; novel endpoints; reduced recall bias | Fit-for-purpose validation burden; model drift; missing data | FDA DHT Framework (2025); context-of-use definition and fit-for-purpose validation required |
| Real-Time Safety Monitoring | Continuous data ingestion, signal detection, HALO/Elsa 4.0 | Eliminates phase hiatus; accelerates regulatory decisions | Data quality compressed; unverified data risks; confidentiality concerns | Proof-of-concept phase; RTCT pilot program launching summer 2026 |
Clinical and Ethical Considerations
Algorithmic bias represents the most consistently documented risk. Models trained on data from predominantly White, urban, or insured populations perform poorly across underrepresented groups. The FDA and EMA both require that training data be balanced and sufficiently large for the intended COU, with explicit subgroup analyses and documented mitigation strategies 27. Post-hoc fairness adjustments—such as those used in DocTr—can improve representational metrics but may not address root causes embedded in source data.
Informed consent and transparency require that patients understand when AI influences their recruitment, eligibility assessment, or care within a trial. Cybersecurity considerations are equally important: EHR-based platforms require HIPAA and GDPR-compliant data governance, encryption, access controls, and privacy impact assessments 2427.
Model drift—the degradation of AI performance over time as patient populations, clinical practices, or data collection processes evolve—demands ongoing monitoring, predetermined change control plans, and transparent reporting. Both the FDA and EMA specify that models in late-stage, high-risk settings must be frozen before database lock; post-lock modifications are treated as exploratory 27. Clinician and trialist oversight must be preserved: qualitative interviews with oncology professionals confirm that while automating prescreening is welcomed, final eligibility decisions must remain under human authority 4.
Table 2: Regulatory and Implementation Considerations Across FDA, EMA, and NMPA (2026)
| Consideration | FDA Expectations | EMA Expectations | NMPA Approach | Common Implementation Barrier |
|---|---|---|---|---|
| Transparency and Documentation | Seven-step credibility assessment; full disclosure of model architecture, training data, validation | AI treated as part of clinical dossier; full transparency on model logic, limitations, biases | Aligned with FDA/EMA; technical guidelines for large-model AI under development | Resource-intensive documentation; vendor reluctance to disclose proprietary models |
| Data Governance and Privacy | Fit-for-use data; training data characterization; HALO cross-center access with CCI concerns | GDPR compliance; data protection-by-design; explicit controls for EU participant data | Information-sharing procedures for multinational trials; cross-border governance defined | Complexity of multi-jurisdictional data flows; HIPAA/GDPR compliance |
| Human Oversight and Explainability | Human-in-the-loop required; SHAP/LIME preferred; black-box models require risk management | Human expert review mandatory for AI-generated evidence; transparent models preferred | Aligned with FDA/EMA; human subject matter expert verification emphasized | Tension between model performance and interpretability; resource requirements for review |
| Bias and Fairness | Diverse training data; subgroup performance analysis; explicit bias mitigation | Exploratory analyses documenting biases; fairness entropy metrics; equity-focused design | Representativeness in training data; performance evaluation databases | Sparsity of minority populations in EHR/claims data; post-hoc adjustments insufficient |
| Model Freeze and Prespecification | Freeze before database lock; post-lock modifications treated as post hoc; incremental learning not accepted | Prespecification in protocol/SAP; model freeze before database lock | Simplified change registration if core algorithm unchanged; performance optimization permitted | Operational complexity; tension with adaptive/continuously learning systems |
| Early Regulatory Engagement | FDA pre-submission meetings encouraged; Chief AI Officer available | EMA Innovation Task Force and Scientific Advice Working Party pathways available | NMPA information-sharing procedures; expert consultation mechanisms | Variable reviewer familiarity with AI methodologies; unclear engagement timelines |
Future Outlook
Over the next two to five years, several directions are likely to shape AI in trial design. Decentralized and hybrid trial models, combining remote monitoring and direct-to-patient outreach with AI-driven eligibility matching and endpoint adjudication, are expected to expand access to underrepresented populations. Real-time and continuous trials—exemplified by the FDA's RTCT program—will require new data quality architectures and compressed regulatory interaction timelines 29. Generative AI for protocol development will accelerate iteration, but quality control requirements and hallucination risks will sustain the need for hybrid workflows in which AI drafts and human experts validate 25. Regulatory-grade validation frameworks, building on the FDA/EMA joint principles and NMPA alignment, are expected to converge toward internationally harmonized standards through ICH and IMDRF forums, facilitating—though not eliminating—the burden of multinational trial governance 127.
A concordance study of AI-based oncology RCT protocols against SPIRIT-AI 2020 reporting guidelines found median concordance of 78.21%, with critical gaps in handling of poor-quality data (58.33%), performance error analysis (50%), and code accessibility (41.67%) 3. Closing these reporting gaps—through journal mandates and regulatory requirements—will be essential to enabling reproducibility and responsible integration of AI into clinical practice.
Conclusion and Practical Takeaways
AI in clinical trial design has moved from theoretical promise to regulated practice by 2026, with the strongest evidence supporting patient recruitment and eligibility matching, where screening efficiency gains of up to 95% have been documented. Adaptive trial designs and RAR offer meaningful sample size reductions. Protocol automation platforms are advancing rapidly. However, implementation remains in an early-adoption phase for many applications, with significant gaps in reporting quality, data interoperability, and validation rigor.
For medical professionals and clinical researchers, the following principles are essential:
- Define context of use explicitly: Every AI application should have a clear, documented role, scope, and target population before deployment.
- Prioritize human oversight: AI tools are decision-support systems; qualified clinicians and statisticians retain final authority over eligibility, endpoint, and safety determinations.
- Conduct systematic bias assessments: Document training data provenance, representativeness, and known limitations; implement fairness metrics and mitigation strategies throughout the model lifecycle.
- Engage regulators early: For high-impact applications, pre-submission dialogue with the FDA, EMA Scientific Advice Working Party, or NMPA avoids costly late-stage regulatory surprises.
- Plan for model drift: Establish predetermined change control plans, continuous performance monitoring, and rapid remediation mechanisms before deployment.
- Maintain audit-ready documentation: Version control, change logs, and traceable records of AI contributions to design decisions are non-negotiable under GxP expectations.
The regulatory landscape will continue to evolve rapidly. The path forward requires balancing technological ambition with disciplined governance, ensuring that every AI-driven decision in clinical development is transparent, accountable, and ultimately in service of patient safety.